Gossamer Bio (NASDAQ:GOSS) Releases Quarterly Earnings Results, Misses Expectations By $3.57 EPS

Gossamer Bio (NASDAQ:GOSS) posted its quarterly earnings data on Tuesday. The company reported ($7.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.79) by ($3.57), FiscalAI reports. The firm had revenue of $38.43 million during the quarter, compared to analyst estimates of $12.16 million.

Gossamer Bio Trading Up 3.6%

Shares of NASDAQ:GOSS opened at $11.69 on Thursday. Gossamer Bio has a 12 month low of $8.29 and a 12 month high of $309.60. The firm’s 50-day moving average is $10.67 and its 200 day moving average is $34.94.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on GOSS shares. Wall Street Zen downgraded Gossamer Bio from a “hold” rating to a “sell” rating in a research report on Sunday, September 20th. Leerink Partners upgraded Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 price target on the stock in a report on Tuesday, July 28th. Chardan Capital restated a “buy” rating on shares of Gossamer Bio in a research report on Monday, October 26th. HC Wainwright reaffirmed a “buy” rating on shares of Gossamer Bio in a research note on Thursday, August 27th. Finally, Wedbush cut their price objective on shares of Gossamer Bio to $32.00 and set a “neutral” rating on the stock in a research report on Wednesday. Five research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $246.40.

About Gossamer Bio

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for diseases with significant unmet medical needs. The company concentrates primarily on immunology, inflammation and pulmonary disorders. Its lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways involving platelet-derived growth factor, colony-stimulating factor 1 and stem cell factor receptors. Gossamer is developing seralutinib for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.